Select a medication above to begin.
methylguanidine acetic acid
creatine
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- amyotrophic lateral sclerosis [Possibly Ineffective]
- arsenic poisoning [Insufficient Evidence]
- athletic performance [Possibly Effective]
- cerebral creatine deficiency syndromes [Possibly Effective]
- CHF [Insufficient Evidence]
- CKD [Insufficient Evidence]
- cognitive decline, age-related [Insufficient Evidence]
- cognitive function [Insufficient Evidence]
- COPD [Insufficient Evidence]
- depression [Insufficient Evidence]
- diabetes mellitus, type 2 [Insufficient Evidence]
- fatigue [Insufficient Evidence]
- fatigue, post-stroke [Insufficient Evidence]
- fibromyalgia [Insufficient Evidence]
- gyrate atrophy [Insufficient Evidence]
- hereditary motor and sensory neuropathy [Insufficient Evidence]
- Huntington dz [Possibly Ineffective]
- hyperhomocysteinemia [Insufficient Evidence]
- idiopathic inflammatory myopathies [Insufficient Evidence]
- juvenile idiopathic arthritis [Insufficient Evidence]
- McArdle dz [Insufficient Evidence]
- memory [Insufficient Evidence]
- mitochondrial myopathies [Insufficient Evidence]
- multiple sclerosis [Insufficient Evidence]
- muscle breakdown [Insufficient Evidence]
- muscle cramps [Insufficient Evidence]
- muscle strength [Possibly Effective]
- muscle wasting, HIV/AIDS-related [Insufficient Evidence]
- muscular dystrophy [Insufficient Evidence]
- neonatal apnea [Insufficient Evidence]
- osteoarthritis [Insufficient Evidence]
- osteopenia [Possibly Ineffective]
- Parkinson dz [Insufficient Evidence]
- peripheral arterial dz [Insufficient Evidence]
- postop recovery [Insufficient Evidence]
- Rett syndrome [Insufficient Evidence]
- rheumatoid arthritis [Insufficient Evidence]
- sarcopenia [Possibly Effective]
- schizophrenia [Insufficient Evidence]
- skin aging [Insufficient Evidence]
- spinal cord injury [Insufficient Evidence]
- spinal muscular atrophy [Insufficient Evidence]
- traumatic brain injury [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
arsenic poisoning
- [Insufficient Evidence]
- Dose: 3 g PO qd
athletic performance
- [Possibly Effective]
- Dose: 2.25-35 g PO qd; Alt: 240-250 mg/kg/dose PO qd; 10 g PO tid; 5 g PO qid x7 days, then 5 g PO qd
cerebral creatine deficiency syndromes, peds pts
- [Possibly Effective]
- Dose: 400-800 mg/kg/dose PO qd; Alt: 4-8 g PO qd
CHF
- [Insufficient Evidence]
- Dose: 20 g PO qd
CKD
- [Insufficient Evidence]
- Dose: 20 g PO qd x1wk, then 5 g PO qd x1wk, then cont. alternating every other week
cognitive decline, age-related
- [Insufficient Evidence]
- Dose: 0.95 g PO qd; Alt: 5 g PO qid
COPD
- [Insufficient Evidence]
- Dose: 5.7 g PO tid x2wk, then 5.7 g PO qd; Alt: 0.3 g/kg/dose PO qd x1wk, then 0.07 g/kg/dose PO qd
depression
- [Insufficient Evidence]
- Dose: 5 g PO qd
diabetes mellitus, type 2
- [Insufficient Evidence]
- Dose: 3-10 g PO qd; Alt: 3 g PO bid
fatigue
- [Insufficient Evidence]
- Dose: 20 g PO qd
fatigue, post-stroke
- [Insufficient Evidence]
- Dose: 0.1 g/kg/day PO in divided doses; Start: 0.3 g/kg/day PO divided qid x7 days
fibromyalgia
- [Insufficient Evidence]
- Dose: 5 g PO qd; Start: 5 g PO qid x5 days
gyrate atrophy
- [Insufficient Evidence]
- Dose: 1.5 g PO qd
hyperhomocysteinemia
- [Insufficient Evidence]
- Dose: 5 g PO qd
idiopathic inflammatory myopathies
- [Insufficient Evidence]
- Dose: 3 g PO qd; Start: 20 g PO qd x8 days
juvenile idiopathic arthritis
- [Insufficient Evidence]
- Dose: 750 mg PO bid
McArdle dz
- [Insufficient Evidence]
- Dose: 60 mg/kg/dose PO qd; Start: 150 mg/kg/dose PO qd x5 days
mitochondrial myopathies
- [Insufficient Evidence]
- Dose: 2 g PO bid; Start: 5 g PO bid x2wk
muscle breakdown
- [Insufficient Evidence]
- Dose: 5 g PO qid
muscle cramps
- [Insufficient Evidence]
- Dose: 12 g PO x1; Start: before each hemodialysis
muscle strength
- [Possibly Effective (PO route)]
- Dose: 1.25-27 g PO qd; Alt: 0.1-0.3 g/kg/day PO divided qd-bid; Info: may load 20-26 g/day PO divided qd-qid
- [Possibly Effective (topical route)]
- Dose: apply 3.5 mL cream topically qd; Info: 1% cream
muscular dystrophy
- [Insufficient Evidence]
- Dose: 3-5 g PO qd; Alt: 0.1 g/kg/dose PO qd; 20 g PO qd x1wk, then 5 g PO qd
osteoarthritis
- [Insufficient Evidence]
- Dose: 5 g PO qd; Start: 20 g PO qd x1wk
Parkinson dz
- [Insufficient Evidence]
- Dose: 5 g PO bid
rheumatoid arthritis
- [Insufficient Evidence]
- Dose: 5 g PO qid x5 days, then 3 g PO qd; Alt: 5 g PO qid x5 days, then 0.5 g PO qid
sarcopenia
- [Possibly Effective]
- Dose: 20 g/day PO qd-qid x5-7 days, then 2-10 g PO qd; Alt: 0.1 g/kg/dose PO qd
skin aging
- [Insufficient Evidence]
- Dose: apply 0.2% cream topically qd
spinal cord injury
- [Insufficient Evidence]
- Dose: 20 g PO qd
traumatic brain injury, peds pts
- [Insufficient Evidence]
- Dose: 0.4 g/kg/dose PO qd
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.